Skip To Main Content
Cohen JA on Muck Rack

Cohen JA

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Cohen JA’s profile

Articles by Cohen JA

Implementation of an evidence-based trauma-focused treatment for traumatised children and their families during the war in Ukraine: a project description - PubMed

|
By Cohen JA, Weyler Mueller H
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (624) Issue with article?

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results.

|
By Cohen JA
| ncbi.nlm.nih.gov
Conflict of interest statement Conflict of interest statement: Jeffrey Cohen reports personal compensation for consulting for Convelo, Population Council; speaking for Mylan; and serves as an Editor of Multiple Sclerosis Journal.
Open in Who Shared Issue with article?

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

|
By Cohen JA
| ncbi.nlm.nih.gov
Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0.5 or 1 mg) or placebo. After 24 weeks, participants could enter a 2-year, dose-blinded extension.
Open in Who Shared Issue with article?

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

|
By Hartung HP, Cohen JA, Zhang-Auberson L
| ncbi.nlm.nih.gov
Background: In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a.
Open in Who Shared Issue with article?
Show More